배경이미지

Company Overview

AM Sciences was established in 2016 with a goal of developing global new drugs.

AM Sciences is developing the essential therapeutic agent for hepatitis B virus (HBV), which is in need of complete cure.

At the same time, AM Sciences is aiming to become the 'engine' of new drug development. In particular, we are acting as a liaison between global biopharm companies and founders with creative and innovative research results which enables an efficient drug development.

 

The core members of AM Sciences are composed of researchers with diverse experiences in various fields of drug development.

They have experiences in developing and launching a number of new drugs in the global pharmaceutical industry and also have established a new drug venture company, entering a number of drug candidates into clinical trials. In addition, they have experiences in incubating a venture company in the early stage of establishment, leading to success in technology transfer or M&A.

 

These experiences in drug development with the global network of our core members will make a great progress by acting synergistically with creative ideas and efforts of AM Sciences researchers in the development of new drugs.

 
Co-founders
1.jpg Kim, Sohyung CEO

Vice-president of Kainosmed, Secretary General of KBVA, Bachelor’s at Ewha Womans University

2.jpg Jeong, Nakcheol CSO

Chemistry Professor at Korea University, Vice Director of HIT, Princeton University Ph.D.

3.jpg Kim, Kyunhwan Professor at Medical Konkuk University

Senior researcher at Lotte central laboratory, Senior researcher at Protheon, Yonsei University Ph.D.

4.jpg Peppi Prasit Ph.D.  

Inception Sciences CEO, Co-founder of Amira pharmaceuticals, Director of Chemistry Department at Merck

5.jpg Gianni Gromo M.D.  

Versant Ventures Partner, Director of R&D at Roche, Head of China R&D at Roche, Director of NOVIRA

6.jpg Bradley Bolzon Ph.D.  

Managing Director at Versant Ventures, Inc., Vice president at Roche, BD/CRO-related work at Eli Lilly, Transferred compound from NOVIRA to J&J

Scientific Leads

 

Yeongsik Jung KRICT, Medical chemistry

 

Subong Han KRICT, Medical chemistry

 

Woochan Son Asan Medical Centre, Toxicology

 

Juyeon LEE KRICT, Computer modeling

 

Seonju Ahn KRICT, ADME

 

Andy Bader Mirna Therapeutics, Inc., Oncology